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Amorphic mutations in the NF-kB essential modulator (NEMO) cause X-dominant incontinentia pigmenti, which
is lethal in males in utero, whereas hypomorphic mutations cause X-recessive anhidrotic ectodermal dysplasia with
immunodeﬁciency, a complex developmental disorder and life-threatening primary immunodeﬁciency. We charac-
terized the NEMO mutation 110_111insC, which creates the most-upstream premature translation termination
codon (at codon position 49) of any known NEMO mutation. Surprisingly, this mutation is associated with a pure
immunodeﬁciency. We solve this paradox by showing that a Kozakian methionine codon located immediately
downstream from the insertion allows the reinitiation of translation. The residual production of an NH2-truncated
NEMO protein was sufﬁcient for normal fetal development and for the subsequent normal development of skin
appendages but was insufﬁcient for the development of protective immune responses.
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The human IKBKG locus is located on chromosome
Xq28 and encodes NEMO. Amorphic NEMO muta-
tions are associated with a complete lack of NF-kB ac-
tivation via the classical pathway. They are responsible
for incontinentia pigmenti (IP), an X-linked dominant
disorder that is lethal in hemizygous males in utero and
is characterized by abnormalities in ectoderm-derived
tissues, including the skin, eyes, CNS, and teeth, in het-
erozygous females. About 85% of patients with IP who
have NEMO mutations carry a complex rearrangement
of the NEMO gene that results in a frameshift deletion
of exons 4–10 and encodes a putative truncated protein
consisting of the ﬁrst 133 N-terminal amino acids. A
number of other IP-causing mutations have been iden-
tiﬁed in exons 2–10, including mutations associatedwith
premature stop codons (Smahi et al. 2000; Aradhya et
al. 2001b; Fusco et al. 2004). Blood leukocytes and ﬁ-
broblasts expressing the mutated X-chromosome are se-
lectively eliminated around the time of birth, leading to
skewed X-inactivation in female carriers (Parrish et al.
1996).
Other NEMO mutations are hypomorphic, since they
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impair but do not abolish NF-kB activation via the clas-
sical pathway. They are associated with two closely re-
lated but distinct X-recessive (XR) forms of anhidrotic
ectodermal dysplasia (EDA) with immunodeﬁciency
(ID). A mutation of the stop codon (X420W) results in
the more severe syndrome of osteopetrosis (O), lym-
phoedema (L), and EDA-ID (XR-OL-EDA-ID) (Smahi
et al. 2000; Do¨fﬁnger et al. 2001; Mansour et al. 2001;
Dupuis-Girod et al. 2002). Most of the other mutations,
including a few mutations creating premature stop co-
dons, cause XR-EDA-ID without OL (Abinun et al.
1996; Zonana et al. 2000; Aradhya et al. 2001a; Do¨f-
ﬁnger et al. 2001; Jain et al. 2001; Kosaki et al. 2001;
Mansour et al. 2001; Dupuis-Girod et al. 2002; Orange
et al. 2002; Carrol et al. 2003; Jain et al. 2004; Nishi-
komori et al. 2004; Orange et al. 2004a, 2004b; Puel
et al. 2004; Ku et al. 2005a, 2005b). The clinical features
of EDA typically include the poor development of skin
appendages, resulting in hypo- or anhidrosis with dry
skin and heat intolerance; hypo- or atrichosis with sparse
hair, eyebrows, and eyelashes; and hypo- or anodontia
with conical incisors (Priolo and Lagana 2001; Ku et al.
2005a).
Patients with XR-EDA-ID suffer less from develop-
mental defects than from severe infections, most of
which are caused by pyogenic bacteria andmycobacteria
(Abinun et al. 1996; Smahi et al. 2000; Zonana et al.
2000; Aradhya et al. 2001a; Do¨fﬁnger et al. 2001; Jain
et al. 2001; Dupuis-Girod et al. 2002; Orange et al.
2002, 2004a; Carrol et al. 2003; Niehues et al. 2004;
Nishikomori et al. 2004; Ku et al. 2005a). In a few cases,
infections with fungi (Zonana et al. 2000; Do¨fﬁnger et
al. 2001; Dupuis-Girod et al. 2002; Orange et al. 2004a)
and viruses (Do¨fﬁnger et al. 2001; Orange et al. 2002,
2004a) have been documented. Almost half the known
patients with XR-EDA-ID died of infection. The most
consistent immunological abnormality found in these
patients is a poor serum-antibody response to polysac-
charide antigens (reviewed by Puel et al. [2004]; Ku et
al. [2005b]). Two unrelated patients bearing muta-
tions in NEMO, with pure IDs and no apparent devel-
opmental defect—ID without EDA—were recently de-
scribed (Niehues et al. 2004; Orange et al. 2004b). The
ﬁrst patient carries a splice mutation 1056(1)GrA
(Orange et al. 2004b), which results in the skipping
of exon 9, with a premature stop codon inserted at po-
sition 373. We report here the characterization of the
110_111insC mutation in exon 2 in the second patient
(Niehues et al. 2004).
The patient’s clinical features have been reported in
detail elsewhere (Niehues et al. 2004). This patient, a
boy, was the only child of healthy nonrelated Polish par-
ents living in Germany. From the age of 15 mo, he suf-
fered from multiple episodes of disseminated Mycobac-
terium avium disease (affecting mostly lymph nodes and
bones). At the age of 7 years, he was diagnosed with
bronchiectasis caused by Haemophilus inﬂuenzae and
Streptococcus pneumoniae. At the age of 11 years, the
patient presented extra-intestinal disease caused by Sal-
monella enteritidis.He presented severe autoimmune he-
molytic anemia at the age of 12 years and died from
herpes simplex virus 1 (HSV-1) meningo-encephalitis at
the age of 12 years and 10 mo.
The immunological work-up of this patient, from the
age of 2 years, showed low IgA and IgG levels, with
markedly high serum IgM levels. No serum antibodies
against diphtheria toxoid and tetanus toxoid were de-
tected, and titers of antibodies againstH. inﬂuenzaewere
low despite complete routine vaccination. The patient
also presented low serum titers of antibodies against S.
pneumoniae and had no allo-hemagglutinin antibodies.
Known molecular causes of hyper IgM syndrome, in-
cluding defects in CD40, CD154, and activation-induced
cytidine deaminase, were excluded. Because of the pa-
tient’s low serum IgG levels, prophylactic intravenous
immunoglobulin replacement therapy was initiated at 2
years of age and continued until his death. The numbers
of T, B, and NK lymphocytes and the proportions of the
CD4 and CD8 T lymphocyte subsets were within nor-
mal ranges at the ages of 2 and 4 years. However, the
patient lacked memory B cells, since all his B cells had
the naive IgDCD27 phenotype. The proliferative re-
sponses of T lymphocytes to mitogens (PHA and PWM)
were normal.
Genomic DNA was isolated from whole blood cells,
granulocytes, SV40-transformed ﬁbroblasts, and Epstein
Barr virus (EBV)–transformed B cells by a standard phe-
nol/chloroform extraction method. Total RNA was iso-
lated from SV40-transformed ﬁbroblasts by use of Trizol
(GibcoBRL Life Technologies, Invitrogen SARL). Both
cDNA and individual IKBKG exons were ampliﬁed us-
ing speciﬁc primers (primers and conditions for PCR
ampliﬁcation and sequencing are available on request),
were sequenced using the Big Dye Terminator cycle se-
quencing kit (Applied Biosystems), and were analyzed
on an ABI Prism 3700 apparatus (Applied Biosystems).
The X-chromosome inactivation status was evaluated
by the analysis of DNA methylation at the human an-
drogen receptor gene (HUMARA), as described else-
where (Allen et al. 1992). In brief, genomic DNA (200
ng) extracted from whole blood was digested with 10
IU of HpaII (Invitrogen SARL) at 37C overnight, in 50
ml of ﬁnal reaction mixture. After digestion, the reaction
was stopped by incubation of the mixture at 95C for
6 min. A mock sample as control was prepared simul-
taneously without the HpaII. Twenty-ﬁve microliters of
each digested product was then used in a 50-ml PCR
containing 200 mM of dinucleotide triphosphate (Invi-
trogen SARL), 1 IU of Taq polymerase (AmpliTaq; Ap-
plied Biosystems), 1.5 mM of MgCl2, 50 mM of KCl,
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10 mM of Tris-HCl (pH 8.3), and 20 mM of each primer.
The primers used were AR-F 5′-GCTGTGAAGGTTGC-
GTTCCTCAT-3′ and AR-R 5′-TCCAGAATCTGTTCC-
AGAGCGTGC-3′; the AR-F was ﬂuorescent. After an
initial denaturation step at 95C, samples were ampliﬁed
for 30 cycles (1 min at 94C, 1 min at 62C, and 1 min
at 72C), with a ﬁnal extension step for 10 min. Two
microliters of PCR products (mock andHpaII) were then
added to a mixture containing 10 ml of deionized for-
mamide and 0.1 ml molecular weight standard GENES-
CAN 400HD (ROX). The samples were denatured for
6 min at 95C, were cooled on ice, and were resolved
using the 3100 ABI Prism Genetic Analyzer (Applied
Biosystems). The percentage of inactivation was calcu-
lated as reported elsewhere (Chitnis et al. 2000).
Total or nuclear cell extracts were prepared from
SV40-transformed ﬁbroblasts or 293T HEK cells left
unstimulated or stimulated with TNF-a (20 ng/ml; R&D
Systems Europe) or IL-1b (20 ng/ml; R&D Systems Eu-
rope). Electrophoresis, western blot, and electrophor-
etic mobility shift assay (EMSA) were performed as de-
scribed elsewhere (Do¨fﬁnger et al. 2001; Picard et al.
2003). The rabbit anti-human IKKa (H-744, sc-7218),
mouse anti-human IKKb (H-4, sc-8014), mouse anti-
human STAT-2 (A-7, sc-1668), rabbit anti-mouse p38
(C-20, sc-535), mouse anti-human IKKg (B-3, sc-8032),
goat anti-human IKKg (M-18, sc-8256), and rabbit
anti-human IkBa (C-21, sc-37) antibodies were pur-
chased from SantaCruz Biotechnology (Tebu-Bio S.A.).
The mouse anti-human IKKg/NEMO (611306) was pur-
chased from BD Transduction Laboratories (Becton
Dickinson France S.A.S.), the mouse anti-human IKKg/
NEMO (557383) was purchased from BD Pharmingen
(Becton Dickinson France S.A.S.), the rabbit anti-human
IKKg/NEMO (3328) and anti-IkB (1775) antibodies
were kindly provided by G. Courtois and A. Israel, and
the mouse anti-V5 monoclonal antibody (5960-25) was
purchased from Invitrogen (Invitrogen SARL). The
EMSA was performed by incubating 10 mg of nuclear
extract with a 32P-labeled double-stranded NF-kB–spe-
ciﬁc oligonucleotide kB probe (5′-GATCATGGGGAA-
TCCCCA-3′ and 5′-GATCTGGGGATTCCCCAT-3′).
Supershift experiments were performed with goat anti-
human p50 (C-19, sc-1190) and rabbit anti-human p65
(C-20, sc-372) antibodies from Santa Cruz Biotechnol-
ogy (Tebu-Bio S.A.).
Cytokine production was assessed in whole blood di-
luted 1:2 in RPMI 1640 (GibcoBRL Life Technologies)
and activated with TNF-a (20 ng/ml; R&D Systems
Europe), IL-12p70 (20 ng/ml; R&D Systems Europe),
IL-1b (20 ng/ml; R&D Systems Europe), IL-18 (50 ng/
ml; R&D Systems Europe), and IL-12 plus IL-18 or
phorbol 12-myristate 13-acetate (PMA) plus ionomycin
(107 M and 105 M, respectively) (Sigma-Aldrich
Chimie SARL) for 48 h. For toll-like receptor (TLR)–
agonist activation, whole blood diluted 1:5 in RPMI
1640 (GibcoBRL) was incubated with polymyxin B (10
mg/ml; Sigma-Aldrich) (except for stimulation by gram-
negative bacteria and lipopolysaccharide [LPS]) at 37C
for 30 min. Cells were then activated with TLR ligands:
PAM3CSK4 (100 ng/ml; EMC Microcollections), which
mimics gram-negative bacteria, recognized by TLR1 and
TLR2; PAM2CSK4 (100 ng/ml; EMC Microcollections),
which mimics gram-positive Mycoplasma lipoprotein;
zymosan A from yeast (125 mg/ml; Molecular Probes,
Invitrogen SARL) and peptidoglycan from Staphylococ-
cus aureus (30 mg/ml; Sigma-Aldrich), recognized by
TLR2 and TLR6; lipoteichoic acid from S. aureus (50
mg/ml; Sigma-Aldrich), recognized by TLR2; poly(I:C)
double-stranded RNA (50 mg/ml; Sigma-Aldrich), which
mimics RNA viruses, recognized by TLR3; LPS from
Salmonella minnesota R595 (10 mg/ml; Sigma-Aldrich),
recognized by TLR4; ﬂagellin from the ﬂagellated gram-
negative bacterium Salmonella typhimurium (10 ng/ml;
provided by K. D. Smith, Institute for Systems Biology),
recognized by TLR5; imidazoquinoline 3M-13, recog-
nized by TLR7 (provided by 3M Pharmaceuticals and
3M Innovative Properties); and CpG oligonucleotide
DNA (5′-TCGTCGTTTTGTCGTTTTGTCGTT-3′) (20
mg/ml; Research Genetics, Invitrogen SARL), recognized
by TLR9. Several TLR agonists were kindly provided
by Adrian Ozinsky. Whole bacteria were also used: heat-
killed S. aureus (5#106 particles/ml; ATCC, LGC Prom-
ochem), Escherichia coli (5#106 particles/ml; ATCC),
and H37Rv strain of Mycobacterium tuberculosis (M.
tb) (1 mg/ml; provided by J. Belisle, TB Research Ma-
terials and Vaccine Testing Contract, NIH, NIAID NO1
AI-75320). For Bacille Calmette-Gue´rin (BCG) activa-
tion, whole blood was diluted 1:2 in RPMI 1640
(GibcoBRL Life Technologies) and was incubated for 12
or 48 h with live BCG (Mycobacterium bovis BCG, Pas-
teur substrain) at a multiplicity of infection of 20:1,
BCG plus IFN-g (5,000 IU/mL), and BCG plus recom-
binant IL-12p70 (20 ng/ml; R&D Systems Europe). Su-
pernatants were collected after 12 or 48 h, and the se-
cretion of IL-12p40, IFNg, IL-6, IL-10, and TNF-a was
measured using human IL-12p40 (R&D Systems Eu-
rope), IFNg, IL-6, IL-10, and TNF-a (Sanquin, Mast
Diagnostic) ELISA kits, respectively, in accordance with
the manufacturer’s instructions. For SV40-transformed
ﬁbroblast activation, cells were activated by incubation
for 18 h with TNF-a or IL-1b (10 ng/ml; R&D Systems
Europe), and IL-6 production was measured by ELISA
(Sanquin, Mast Diagnostic). In vitro B-cell proliferation
was measured in peripheral blood lymphocytes stimu-
lated by incubation for 5 d with sCD154 (1 mg/ml; Am-
gen France), by the addition of 3H-thymidine for the
ﬁnal 18 h (1 mCi). IgE production was measured by
ELISA in the supernatants of peripheral blood lympho-
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Figure 1 Sequencing of the NEMO gene in the patient and his relatives. A, Automated reverse-sequencing proﬁle showing the 110_111insC
mutation in genomic DNA extracted from peripheral blood cells from the hemizygous patient, compared with a control (WT) with the
corresponding amino-acid sequence, and the M38 reinitiation site (boxed). B, Pedigree of the family. Each generation is designated by a roman
numeral (I–III) and each individual is designated by an arabic numeral (1–3); the hemizygous patient is shown in black. Heterozygous carriers
are shown with a black dot in the center. C, X-inactivation pattern in blood cells from a healthy female control, from a female patient with
IP carrying the common IP NEMO ex4_10del mutation, and from the patient’s mother.
cytes stimulated for 12 d with sCD154 plus IL-4 (100
U/ml; R&D Systems Europe).
The full-length human IKBKG cDNA, inserted be-
tween the HindIII and NotI sites of the expression vector
pcDNA3, was a gift from G. Courtois. We generated
various IKBKG mutations, using the QuikChange
Site-Directed Mutagenesis kit (Stratagene) in accor-
dance with the manufacturer’s procedure. The patient’s
110_111insC mutation was generated using the primers
P-CCTCTGGGGAAGCCAGCCCATGCTGCACCTG-
CCTTC and P-GAAGGCAGGTGCAGCATGGGCTG-
GCTTCCCCAGAGG, the IP mutation R62X using
the primers P-GAGAATCAAGAGCTCTGAGATGCC-
ATCCGGCAG and P-CTGCCGGATGGCATCTCAG-
AGCTCTTGATTCTC, the XL-OL-EDA-ID mutation
X420W using the primers P-CATGGAGTGCATTG-
AGTGGGGCCGGCCAGTGCAAGG and P-CCTTGC-
ACTGGCCGGCCCCACTCAATGCACTCCATG, the
mutation M38A (the hypothetical translation reinitia-
tion methionine) using the primers P-CCTCTGGGGAA-
GCCAGCCGCGCTGCACCTGCCTTCAGAAC and P-
GTTCTGAAGGCAGGTGCAGCGCGGCTGGCTTC-
CCCAGAGG, the double mutation 110_111insC/
M38A using the primers P-CCTCTGGGGAAGC-
CAGCCCGCGCTGCACCTGCCTTCAGAAC and P-
GTTCTGAAGGCAGGTGCAGCGCGGGCTGGCTT-
CCCCAGAGG, and the mutation M94A (the second
hypothetical translation reinitiation methionine) using
the primers P-GAGGAGAAGGAGTTCCTCGCG-
TGCAAGTTCCAGGAGGCC and P-GGCCTCCT-
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Figure 2 Schematic representation of NEMO with all reported mutations. A, Schematic representation of the coding-region domain
organization: coil-coiled (CC), leucine-zipper (LZ), and zinc-ﬁnger (ZF) domains, and publishedmutations ofNEMO.B, Schematic representation
of all known premature stop codons in NEMO due to nonsense and splice mutations, frameshift insertions, and deletions. For the mutations
leading to a frameshift, the position of the premature stop codon is indicated, with the position of the ﬁrst amino acid affected by the mutation
in parentheses. The mutations associated with XD-IP are shown in black, with XR-OL-EDA-ID in blue, with XR-EDA-ID without OL in red,
with incomplete XR-I-EDA-ID in pink, and with XR-ID without EDA in green.
GGAACTTGCACGCGAGGAACTCCTTCTCCTC.
The mutated fragments were then subcloned into the
pcDNA3.1/V5-His-directional TOPO expression vector
(Invitrogen SARL), in accordance with the manufac-
turer’s instructions.
The various pcDNA3.1/V5-His-TOPO expression
vectors encoding wild-type (WT), 110_111insC, 110_
111insC/M38A, M38A, M94A, R62X, and X420W
NEMO or the insert-free vector were used to transfect
SV40-transformed IP ﬁbroblasts or 293T HEK cells, in
the presence of Lipofectamine 2000 (Invitrogen SARL)
or calcium phosphate (Invitrogen SARL), in accordance
with the manufacturer’s recommendations.
For intracellular NEMO staining, we ﬁxed 2#105 ﬁ-
broblasts or EBV-transformed B cells, permeabilized
them using IntraStain kit (DakoCytomation S.A.S. Trap-
pes Cedex), and incubated them with a mouse anti-hu-
man IKKg/NEMO IgG1 (611306) from BD Transduc-
tion Laboratories (Becton Dickinson France S.A.S.) or
an isotype control mouse IgG1,k, (555746) from BD
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Figure 3 NF-kB signaling in SV40-transformed ﬁbroblasts. A,
Time-course analysis of IkBa protein degradation and resynthesis de-
tected by western blot after stimulation with IL-1b for 20, 40, 60, and
120 min; the antibody against p38 served as a control for protein
loading. B, NF-kB DNA-binding activity, measured by EMSA after
stimulation for 20 and 40 min with IL-1b. g-Activating–factor DNA-
binding activity after 20 min of stimulation with IFN-g and compe-
tition with unlabeled NF-kB–speciﬁc probe (*) served as internal ac-
tivation control and speciﬁcity control, respectively. C, IL-6
production after 18 h of exposure to IL-1b, TNF-a, and PMA/iono-
mycin, in ﬁbroblasts from a healthy control, from the patient, from a
patient with XR-OL-EDA-ID (X420W), and from a patient with XD-
IP (ex4_10del). Results shown are representative of two to three in-
dependent experiments.
Pharmingen (Becton Dickinson France S.A.S.). Cells
were washed and were labeled with an Alexa Fluor 488
goat anti-mouse IgG (A-11029) from Molecular Probes
(Invitrogen SARL), as described elsewhere (Nishikomori
et al. 2004). Cells were analyzed by ﬂow cytometry on
a FACScan apparatus (Becton Dickinson).
The sequencing of genomic DNA and cDNA obtained
from whole blood cells, granulocytes, SV40-transformed
ﬁbroblasts, and EBV-transformed B cells revealed a
frameshift insertion in codon 37 of NEMO exon 2
(110_111insC) generating a premature stop codon 12
residues downstream at codon position 49 (M38fsX48)
(ﬁgs. 1A, 2A, and 2B). The mother, maternal aunt, and
maternal grandmother of this patient were heterozygous
for the mutation (ﬁg. 1B). This previously unreported
mutation was not found in 305 Caucasian controls (190
females and 115 males; 495 chromosomes), suggesting
that it was pathogenic. It creates the furthest upstream
of the known premature stop codons in NEMO—most
others being associated with XD-IP, and the remaining
few, mostly located in the 3′ region of the coding region,
being associated with XR-EDA-ID (ﬁg. 2A and 2B). Par-
adoxically, the 110_111insC mutation was associated
with viable fetal development and a lack of detectable
developmental phenotype in the affected hemizygous
boy. Moreover, the mother presented no clinical signs of
XD-IP and displayed a random pattern of X-chromo-
some inactivation (75% and 25%) in her blood cells
(ﬁg. 1C).
We investigated whether the 110_111insC mutation
was amorphic (as in loss-of-function), as predicted from
genetic ﬁndings, or hypomorphic, as predicted from clin-
ical ﬁndings, by assessing NF-kB activation in SV40-
transformed ﬁbroblasts from a healthy control, from the
patient studied, from a patient with XR-OL-EDA-ID
(bearing the NEMOX420Wmutation), and from a fetus
with XD-IP (bearing the ex4-10del NEMO mutation).
Upon stimulation with TNF-a and IL-1b, IkBa degra-
dation and resynthesis were normal in the patient’s cells,
whereas they were impaired in XR-OL-EDA-ID cells and
were completely abolished in XD-IP cells (ﬁg. 3A and
data not shown). However, the kB DNA-binding activity
of the patient’s cells, measured by EMSA, was approx-
imately one-third that of control ﬁbroblasts—a decrease
similar to that observed with XR-OL-EDA-ID ﬁbro-
blasts. No detectable DNA-binding activity was ob-
served with XD-IP ﬁbroblasts (ﬁgs. 3B and 4). Finally,
IL-6 production was impaired in the patient’s ﬁbroblasts
and, to a greater extent, in XR-OL-EDA-ID ﬁbroblasts,
in response to both IL-1b and TNF-a, whereas it was
completely abolished in XD-IP ﬁbroblasts (ﬁg. 3C).
Thus, the NEMO 110_111insC mutation, despite cre-
ating a stop codon at position 49, was hypomorphic,
since it impaired but did not abolish NF-kB activation
and was even associated with a somewhatmilder cellular
phenotype than the X420W NEMO mutation.
We evaluated the immunological impact of the
NEMO mutation by stimulating the patient’s blood cells
(ﬁg. 5) with TNF-a, IL-1b, or agonists of TLRs. The
response of the patient’s blood cells to TNF-a was re-
producibly impaired, in terms of IL-10 production. In
contrast, the response to IL-1b, LPS (an agonist of TLR-
4), or other TLR agonists—such as heat-killed S. aureus
Cowan, E. coli, and M. tb—was normal, in terms of IL-
6 or TNF-a production. Because the main infectious
disease of this patient was caused by M. avium, a weakly
virulent environmental mycobacterial species, we also
investigated the IL-12/23-IFN-g circuit (Casanova and
Abel 2002). We observed no response to live M. bovis
BCG, BCG plus IL-12, or BCG plus IFN-g, in terms of
IFN-g, IL-12p40, or IL-12p70 production in the pa-
tient’s blood cells. Finally, we tested CD40-mediated
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Figure 4 NF-kB signaling in ﬁbroblasts. Composition of the NF-kB dimers bound to the kB probe, as measured by EMSA in SV40-
transformed ﬁbroblasts from a healthy control, from the patient, from a patient with OL-EDA-ID, and from a patient with IP, after exposure
to IL-1b for 40 min, and as determined using antibodies directed against p50 and p65.
Figure 5 Whole blood cell activation. The legend is available in
its entirety in the online edition of The American Journal of Human
Genetics.
NF-kB activation by measuring B-cell proliferation and
Ig isotype switching upon stimulation with CD40L
(CD154) in vitro. The patient’s cells displayed impaired
proliferation and IgE production in response to CD154,
alone or in combination with IL-4. These results indicate
that the patient’s NEMO mutation was hypomorphic in
blood cells and provide an explanation for the patient’s
immunological phenotype.
We then assessed NEMO production in SV40-trans-
formed ﬁbroblasts from the patient. No protein was de-
tected in the patient’s ﬁbroblasts with the use of a serum
directed against N-terminal amino acids 28–33 of
NEMO (serum 3328), whereas two proteins of ∼48 and
45 kDa were detected in control cells (ﬁg. 6A, left panel),
and a protein of ∼51 kDa appeared with prolonged ex-
posure in the OL-EDA-ID ﬁbroblasts (data not shown).
In contrast, with the use of antibodies directed against
amino acids 278–396 (611306) (data not shown) and
356–414 (M-18) (ﬁg. 6A, right panel), small amounts
of a protein of ∼45 kDa were detected in the control
and patient’s ﬁbroblasts. Neither the 48-kDa nor the 45-
kDa protein was detected with either antibody in XD-
IP ﬁbroblasts, suggesting that the NEMO gene encoded
both proteins. Residual NEMOproduction was detected
by ﬂow cytometry, with use of antibody 611306 in ﬁ-
broblasts (ﬁg. 6B) and EBV-transformed B cells (not
shown) from the patient and from the patient with XR-
OL-EDA-ID. Again, no NEMO was detected in XD-IP
ﬁbroblasts. Thus, the 110_111insC mutant allele en-
codes an N-terminally truncated NEMO protein that is
produced in small amounts. The 110_111insC mutation
probably allows reinitiation of the translation process
downstream from the insertion.
An almost canonically Kozakian methionine AUG
start codon (Kozak 2000, 2002b) is located at nucleotide
positions 112–114, corresponding to methionine 38 (ﬁg.
7A). The likelihood of this AUG codon acting as a trans-
lation initiation site was estimated at 0.27 and increased
to 0.51 in the sequence context found in the patient,
versus 0.63 for the ﬁrst AUG codon (Prediction of Trans-
lation Initiation ATG Web site). Such a reinitiation of
translation would result in the synthesis of a protein ∼45
kDa in size. We, therefore, transfected 293T HEK cells
with V5-tagged expression vectors carryingWT and var-
ious mutant NEMO alleles: M38A (methionine 38 re-
placed by alanine, preventing reinitiation at codon 38)
with or without the 110_111insC, R62X (the most-up-
stream nonsense mutation responsible for XD-IP), and
X420W. With an anti-V5 antibody, a protein of ∼48
kDa was detected in WT- and M38A-transfected cells.
Smaller amounts of a protein of ∼45 kDa were detected
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Figure 6 NEMO production in SV40-transformed ﬁbroblasts. A, NEMO production assessed by western blot analysis, with the use of
antibodies directed against the N- or C-terminal part of NEMO (amino acids 28–33 and 356–414, respectively), antibodies against p38 and
STAT-2 being used as controls for protein loading. B, Intracellular staining with an antibody directed against amino acids 278–396 of NEMO
(black) or an isotype-control antibody (gray) of ﬁbroblasts from a control, from the patient, from a patient with XR-OL-EDA-ID, and from a
patient with XD-IP. Results shown are representative of three independent experiments.
in WT- and 110_111insC-transfected cells, but not in
M38A- or 110_111insC/M38A–transfected cells. A pro-
tein of ∼51 kDa was detected in X420W-transfected
cells, and no speciﬁc proteins were detected in mock-
and NEMO R62X-transfected cells. These results con-
ﬁrmed that the WT NEMO allele encodes two proteins:
the predominant 48-kDa protein and an N-terminally
truncated protein of ∼45 kDa produced in smaller
amounts and translated from methionine 38. This sec-
ond protein is the only isoform detected in the patient’s
cells.
This description of the most-upstream premature stop
codon (at amino-acid position 49, M38fsX48) of any
known NEMO mutation, in a child with ID without
EDA, shows that the location of the premature stop
codon is not correlated with the severity of the clinical
phenotype. Nonetheless, the ID appeared to be partic-
ularly severe, since the patient developed fatal HSV-1
meningo-encephalitis (Niehues et al. 2004), identifying
NEMO deﬁciency as the second genetic etiology of HSV-
1 encephalitis (Dupuis et al. 2003) and suggesting that
the NF-kB–mediated induction of IFN-a/b is essential
for HSV-1 control. The 110_111insC mutation, there-
fore, had a highly deleterious effect on immunity to in-
fection but a much weaker than expected effect on de-
velopment, with normal fetal development and no signs
of EDA in childhood. Studies on the patient’s cells
showed that the 110_111insC NEMO mutation was hy-
pomorphic because of the residual production of an N-
terminally truncated protein resulting from the reinitia-
tion of translation at an internal AUG codon located
immediately downstream from the mutation. This pro-
cess also occurs in control cells. The small amounts of
the resulting NEMO protein were sufﬁcient to trigger
normal responses to some NF-kB dependent signaling
pathways, preventing both fetal death and developmen-
tal disorders in childhood (Smahi et al. 2002).
This rare mechanism has been reported in other in-
herited disorders of leukocytes—such as Omenn’s syn-
drome (RAG1) (Santagata et al. 2000), Fanconi anemia
(FAC) (Yamashita et al. 1996), and Nijmegen breakage
syndrome (NBS1) (Maser et al. 2001)—and in other
ﬁelds of human genetics (Yamashita et al. 1996; Ozisik
et al. 2003; Pittis et al. 2004), upstream premature stop
codons being typically involved (Santagata et al. 2000).
Nevertheless, this compensatory mechanism is only par-
tial, because (1) reinitiation at a secondary AUG is less
efﬁcient than use of the ﬁrst AUG (Kozak 2002a), (2)
truncated proteins are potentially unstable, and (3) trun-
cated proteins are likely to be less functional. There is
currently no documented example of full biological or
clinical complementation of a premature stop codon by
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Figure 7 Expression of various NEMO constructs in vitro. A, WT sequence of the 5′ end of NEMO showing the ﬁrst methionine site
involved in the initiation of translation (M1, boxed), the position of the 110_111insC mutation, the second methionine site (M38) involved in
translation reinitiation, and the IP nonsense mutation at Arg 62 (R62X). B, Western blot analysis with an anti-V5 antibody of 293T HEK cells
transfected with insert-free V5-tagged vector (mock) or with expression vectors carrying various NEMO alleles: WT, 110_111insC (the patient’s
mutation), M38A (the methionine 38 to alanine mutation, blocking reinitiation of translation at M38) with or without the 110_111insC
mutation, X420W, and R62X. Cells were cotransfected with 3 mg of each vector and 1 mg of a myc-tagged expression vector encoding b-
galactosidase, as a transfection-efﬁciency control. An antibody against p38 was used to control for protein loading.
reinitiation of translation. However, some compensation
does occur, the cellular and clinical phenotypes being
milder than predicted from the genotype alone (Yama-
shita et al. 1996; Santagata et al. 2000; Maser et al.
2001). This report therefore adds a further level of com-
plexity to studies of pathogenic mutations in human
NEMO and provides further evidence that the reinitia-
tion of translation is a potentially important compen-
satory mechanism in human genetics, with profound cel-
lular and clinical consequences.
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